



The US Select Agent Rule and an International Opportunity to Achieve Defensible Biosecurity Guidelines



**2004 Asia Regional Workshop:
The Future of the Biotechnology Industry
Singapore
April 27, 2004**

**Reynolds M. Salerno, Ph.D.
Sandia National Laboratories**



Bioterrorist and Biological Weapons Threat

- Increase in awareness of bioterrorist and biological weapons threat in the US
- Emerging US security regime: policies with two sets of objectives
 - Enhance ability to respond to public and agricultural health emergencies
 - Reduce the risk that bioscience and biotechnology could be used maliciously
- Focus of this talk is biosecurity: protection of certain biological materials at bioscience facilities from theft and sabotage




Problem: Bioscience Research and International Security

- Recent realization that bioscience facilities are potential sources of viable and virulent pathogens and toxins
 - Bioscience community not accustomed to security
- New US regulatory environment has broad international repercussions
 - International community must address this issue
- Control of certain biological materials is necessary
 - But *how* that is achieved must be carefully considered and implemented



New US Regulatory Environment for Biosecurity

- **USA PATRIOT Act of 2001 – US Public Law 107-55**
 - **Restricted Persons**
- **Bioterrorism Preparedness Act of 2002 – US Public Law 107-188**
 - **42 CFR 73 (Human)**
 - **9 CFR 121 (Animal)**
 - **7 CFR 331 (Plant)**
- **The CFR require specific measures**
 - **Registration of a facility if they possess one of the 82 Select Agents**
 - **Background checks for individuals with access to Select Agents**
 - **Facility must designate a Responsible Official**
 - **Security, safety, and emergency response plans**
 - **Safety and security training**
 - **Regulation of transfers of Select Agents**
 - **Recordkeeping**
 - **Safety and security inspections**





Human Select Agents and Toxins

- Crimean-Congo haemorrhagic fever virus
- Ebola viruses
- Cercopithecine herpesvirus 1 (Herpes B virus)
- Lassa fever virus
- Marburg virus
- Monkeypox virus
- South American Haemorrhagic Fever viruses (Junin, Machupo, Sabia, Flexal, Guanarito)
- Tick-borne encephalitis complex (flavi) viruses
- Variola major virus and Variola minor virus (Alastrim)
- *Rickettsia prowazekii*
- *Rickettsia rickettsii*
- *Yersinia pestis*
- *Coccidioides posadasii*
- Abrin
- Conotoxins
- Diacetoxyscirpenol
- Ricin
- Saxitoxin
- Tetrodotoxin
- Shiga-like ribosome inactivating proteins



Overlap Select Agents and Toxins

- Eastern equine encephalitis virus
- Nipah and Hendra complex viruses
- Rift Valley fever virus
- Venezuelan equine encephalitis virus
- Botulinum neurotoxins
- *Clostridium perfringens* epsilon toxin
- Shigatoxin
- Staphylococcal enterotoxins
- T-2 toxin
- *Bacillus anthracis*
- *Brucella abortus*
- *Brucella melitensis*
- *Brucella suis*
- *Burkholderia mallei*
- *Burkholderia pseudomallei*
- Botulinum neurotoxin producing species of *Clostridium*
- *Coxiella burnetii*
- *Francisella tularensis*
- *Coccidioides immitis*



Animal Select Agents and Toxins

- African horse sickness virus
- African swine fever virus
- Akabane virus
- Avian influenza virus (highly pathogenic)
- Bluetongue virus (exotic)
- Pox viruses (camel, goat, sheep)
- Classical swine fever virus
- Foot and Mouth Disease virus
- Japanese encephalitis virus
- Lumpy skin disease virus
- Malignant catarrhal fever virus
- Newcastle disease virus
- Peste des petits ruminants virus
- Rinderpest virus
- Swine vesicular disease virus
- Vesicular stomatitis virus (exotic)
- *Cowdria ruminantium*
- *Mycoplasma capricolum*
- *Mycoplasma mycoides*
- Bovine spongiform encephalopathy agent



Plant Select Agents and Toxins

- Plum pox potyvirus
- *Liberobacter africanus*
- *Liberobacter asiaticus*
- *Ralstonia solanacearum*
- *Xanthomonas oryzae*
- *Xylella fastidiosa*
- *Peronosclerospora philippinensis*
- *Phakopsora pachyrhizi*
- *Sclerophthora rayssiae*
- *Synchytrium endobioticum*

Scientific Concerns

- Top-down security regime
- No need to acquire biological material from a bioscience facility to pursue bioterrorism
- Nature of the material makes diversion extremely difficult to prevent
- Dual-use characteristics of biological materials and technology make identification of illegitimate activities extremely difficult



REPORTS

Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template

Jeronimo Cello, Aniko V. Paul, Eckard Wimmer*

9 AUGUST 2002 VOL 297 SCIENCE www.sciencemag.org

Journal of Virology, Feb. 2001, p. 1205-1210
0022-538X/01/040000-06 DOI: 10.1128/JVI.75.3.1205-1210.2001
Copyright © 2001, American Society for Microbiology. All Rights Reserved.

Vol. 75, No. 3

Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox

RONALD J. JACKSON,^{1,2*} ALSTAIR J. RAMSAY,^{2,3} CARINA D. CHRISTENSEN,³ SANDRA BEATON,³ DIANA F. HALL,^{1,2} and IAN A. RAMSHAW¹

Post Animal Control Cooperative Research Centre, CSIRO Sustainable Ecosystems,¹ and Division of Immunology and Cell Biology, John Curtin School of Medical Research, Australian National University,² Canberra, Australia



Security Concerns

- The most likely threat to viable and virulent biological material is from someone who has legitimate access to the facility
 - Traditional facility security approaches focus on protecting against outside adversaries
- Very few agents can be easily and successfully deployed as mass-casualty weapons
 - US regulations based on 82 agents and toxins of various degrees of attractiveness to adversaries
- No protection if personnel do not understand and accept security
 - Evasion of security measures
 - Withdrawal from research on Select Agents





Achieving International Biosecurity

- **“Infectious diseases make no distinctions among people and recognize no borders”**
 - **President George Bush, November 2001**
- **Securing pathogens and toxins must be an international endeavor to mitigate the threat of BW proliferation**
- **International regulatory regime would not be appropriate because of dual-use nature of all bioscience**
- **International guidelines should be promulgated by a respected technical organization in the public health field**
 - **World Health Organization**




Biosafety as a Model

- **Biosafety aims to reduce or eliminate accidental exposure to or release of hazardous agents**
 - CDC/NIH “Biosafety in Microbiological and Biomedical Laboratories” (BMBL)
 - WHO “Laboratory Biosafety Manual” (LBM)
- **Four biosafety levels**
 - Graded application of practices and techniques, laboratory equipment, and facility design (“containment”)
 - Based on agent safety risk assessments
- **Biosafety now considered standard microbiological practice around the world**




Defensible & Achievable Biosecurity Guidelines

- Employ a risk management approach
 - Risk will always exist: every asset cannot be protected against every threat
 - Distinguish between “acceptable” and “unacceptable” risks
- Develop a methodology so that facilities can conduct agent-based security risk assessments
 - Ensures that protection for an asset, and the cost, is proportional to the risk of theft or sabotage of that asset




Biological Agent Security Risk Assessment


- All pathogens and toxins do not need the same level of protection
- Agents should be placed in a Biosecurity Level based upon their risk of theft and use as a biological weapon
 - Risk should be a function of both weaponization potential and consequences of use
- Weaponization potential is the ease or difficulty that an agent may be successfully deployed as a weapon
- Consequences of use are associated with the infectious disease characteristics of the agent




Bacillus anthracis



Coccidioides immitis




Variola major



Mycobacterium leprae

Biological Agent Security Risk Levels

- **Low Risk Pathogens and Toxins (LRPT)**
 - Relatively difficult to deploy as a weapon, and/or
 - Use as a weapon would have few consequences
- **Moderate Risk Pathogens and Toxins (MRPT)**
 - Relatively difficult to deploy as a weapon, and
 - Use as a weapon would have localized consequences with low to moderate casualties and/or economic damage
- **High Risk Pathogens and Toxins (HRPT)**
 - Not particularly difficult to deploy as a weapon, and
 - Use as a weapon could have national or international consequences, causing moderate to high casualties and/or economic damage
- **Extreme Risk Pathogens and Toxins (ERPT)**
 - Would normally be classified as HRPT, except that they are not found in nature (eradicated)
 - Could include genetically engineered agents, if they were suspected of being a HRPT






Results of a Biosecurity-Level System

- **Most pathogens and toxins would likely be LRPT**
- **Most current Select Agents would likely be MRPT**
- **Security associated with LRPT and MRPT would be achievable at reasonable cost for the broad biological research community**
 - **Rely largely on existing biosafety measures**
- **Very few Select Agents would be HRPT or ERPT**
- **Security for facilities that work with HRPT or ERPT would be relatively significant, but should still**
 - **Rely largely on policies and procedures**
 - **Be transparent to the users**
 - **Use resources efficiently**
 - **Not unnecessarily hinder normal operations (e.g. research, diagnostics, biosafety)**

Summary

- **Necessary to take steps to reduce the likelihood that certain pathogens and toxins could be stolen from bioscience facilities**
- **Critical that these steps are designed specifically for biological materials and research**
- **Most biosecurity measures should reinforce and complement existing biosafety measures**
- **Need to involve international scientific community in development of a comprehensive approach and widely accepted model for biosecurity**
 - **Important to build understanding and acceptance**





Contact Information

Reynolds M. Salerno, Ph.D.
Principal Member of the Technical Staff
Sandia National Laboratories
PO Box 5800, MS 1373
Albuquerque, NM 87185
USA
Tel. 505-844-8971
email: rmsaler@sandia.gov

www.biosecurity.sandia.gov

